Abbott Laboratories (ABT)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 7,013,000 | 6,664,000 | 8,306,000 | 8,211,000 | 4,968,000 |
| Revenue | US$ in thousands | 41,950,000 | 40,109,000 | 43,653,000 | 43,075,000 | 34,608,000 |
| Pretax margin | 16.72% | 16.61% | 19.03% | 19.06% | 14.36% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $7,013,000K ÷ $41,950,000K
= 16.72%
Abbott Laboratories has shown a consistent improvement in its pretax margin over the years. The pretax margin increased from 14.36% in December 2020 to 19.06% in December 2021, reflecting a significant improvement in profitability. In the following years, the pretax margin remained relatively stable at around 19%, indicating that Abbott Laboratories has been able to maintain its profitability levels despite potential economic challenges. Although there was a slight decline to 16.61% in December 2023 and a minor increase to 16.72% in December 2024, overall, the company has demonstrated a strong ability to generate earnings before taxes relative to its revenue. This consistent performance suggests efficient cost management and operational effectiveness within Abbott Laboratories.
Peer comparison
Dec 31, 2024